Menu

Report Library

All Reports
Beta Amyloid Antagonists/Inhibitors in Alzheimer’s Disease, Phase III

April 24, 2017

Ongoing and planned industry-sponsored trials in Phase II/III and Phase III for drugs that affect beta amyloid deposits and with mechanisms of action that include beta amyloid precursor protein antagonists, beta amyloid protein antagonists, secretase inhibitors and secretase gamma inhibitors.

Trialscape is a powerful visual analysis tool derived from the comprehensive clinical trials intelligence in Citeline’s Trialtrove. Each Trialscape map displays the current and future competitive landscape of pharmaceutical clinical trials in a specific area of research. The Trialscape solution provides graphical representation of pharmaceutical clinical trial timelines in support of strategic decisions in drug development, clinical operations and marketing.

In addition to the Trialscape maps available for purchase here, Citeline also offers bundled pricing for all maps in a therapeutic area. If your interest is in areas beyond the current inventory, our analysts will work with you to create a custom deliverable. Please contact analytics@citeline.com for more information.
Disease Group Covered: Neurology
Indications Covered: Ischemic Stroke
Premenstrual Dysphoric Disorder (PMDD)
Sleep Apnea
Smoking Cessation

 Additional Resources: